Inclusion Criteria:

          -  Signed informed consent obtained prior to initiation of any study-specific procedures
             or treatment as confirmation of the patient's awareness and willingness to comply with
             the study requirements.

          -  Female patients aged ≥ 18 years.

          -  Histologically confirmed and documented HER2-negative metastatic breast cancer.

          -  Previously untreated first-line chemotherapy.

          -  Patients with at least one measurable lesion according to RECIST criteria at study
             entry.

          -  Documented ER/PgR status.

          -  Prior hormone therapy for metastatic disease is allowed but must stop before study
             entry.

          -  KPS>70.

          -  Life expectancy of ≥12 weeks

        Exclusion Criteria:

          -  Previous chemotherapy for metastatic breast cancer.

          -  Prior adjuvant/neoadjuvant chemotherapy within 6 months prior to first study treatment
             administration.

          -  Prior (radical)radiotherapy for the treatment of metastatic disease or major surgical
             procedure within 28 days prior to the first study treatment,

          -  Inadequate bone marrow function: absolute neutrophil count (ANC): <1.5 x 109/L,
             platelet count<75 x 109/L or hemoglobin <100g/L.

          -  Inadequate liver or renal function, defined as:

               1. Serum (total) bilirubin >2 x the upper limit of normal (ULN) for the institution

               2. AST/SGOT or ALT/SGPT >2.5 x ULN (>5 x ULN in patients with liver metastases)

               3. ALP >2.5 x ULN at baseline (>5 x ULN in patients with liver metastases).

               4. Serum creatinine>140umol/L.

          -  Pregnant or lactating females.

          -  Her-2 positive (ICH +++ or FISH positive).

          -  Symptomatic cerebral parenchyma and/or leptomeningeal metastases.

          -  Other malignancy within the last 5 years, except for adequately treated carcinoma in
             situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited
             basal cell skin cancer.

          -  Pre-existing peripheral neuropathy ≥grade 1 according NCI CTCAE 4.0.

          -  Mental disease or other conditions affecting on the compliance of patients.

          -  Other serious disease or medical condition:

               1. History of uncontrolled seizures, CNS disorders or psychiatric disability judged
                  by the Investigator to be clinically significant precluding informed consent.

               2. Congestive heart failure, or unstable angina, myocardial infarction within ≤6
                  months prior to the first study treatment, uncontrolled hypertension and high
                  risk, uncontrolled arrhythmias.

               3. Uncontrolled acute infection

          -  Inability to take or absorption oral medications.

          -  Concurrent or within 30 days using drugs of other clinical trials.

          -  Previous treatments containing Capecitabine (whether adjuvant or palliative
             treatment).

          -  Previous treatments containing docetaxel within 12 months.

          -  Known hypersensitivity to any of the study treatments or excipients.

          -  Any other conditions the research consider not appropriate to take part in the trial.